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Abstract 
Background: Hospitals are being forced with the task of finding new ways to provide the same 
high level of care at a lower cost.  One possible way of accomplishing this task is through the use 
of Rotational Thrombolelastomety (RoTEM
®
), as a way to guide blood resuscitation in order to 
decrease patient exposure to blood products while decreasing overall hospital costs at the Ohio 
State University Wexner Medical Center.  
Methods:  Utilization of the OSUWMC’s liver transplant quality database allowed for 
comparison of the RoTEM
®
 group to the standard method for intra-operative and 24hr post-
operative blood product usage and its cost for patients that underwent surgery from July 2012 to 
July 30, 2014 at OSUWMC. It also evaluated post-op surgical intervention requirements for 
bleeding. 
Results: There was an average 34.78% reduction in intra-operative blood product usage with an 
average 19.4% cost reduction when utilizing the RoTEM
®
.  There was a decrease in pRBC 
product usage during the first 24hr post-op with an average cost reduction of 49.25% in the 
RoTEM
®




Conclusion: Positive trends can been seen in both decreased blood product exposure to patients 
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Chapter I: Introduction 
Introduction 
 In the current United States healthcare economy medical institutions and providers are 
challenged with the task of providing high quality care at lower costs.  Providers need to find 
ways to use technology in order to work smarter and not harder.  One way of accomplishing this 
task is through the usage of Rotational Thrombolelastomety (RoTEM
®
).  The RoTEM
®
 is a 
point-of-care testing device that aids anesthesia providers in differentiating between surgical 
bleeding and underlying patient coagulopathies (Health Policy Advisory Committee on 
Technology, 2012, p. 2, Kozek-Langenecker, 2005).  This project demonstrates how the usage of 
the RoTEM
®
 can aid providers in blood product administration, allowing them to decrease 
overall blood product usage.  
Problem 
Many times patients receive more blood products than necessary during surgery because 
anesthesia providers lack a quick way to determine the patient’s underlying coagulation or 
bleeding issue.  Traditionally the inability to differentiate between patient coagulopathies verses 
surgical bleeding results in transfusing multiple blood products continuously until the underlying 
issue becomes more apparent.   When administering more blood products than necessary, 
patients are placed at higher risk for developing complications.  Listed in (Table 1) are some 
examples of early and late complications that can occur after blood product transfusion (Maxwell 
& Wilson, 2006, p.225). 
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Table 1: Complications of Blood Transfusion (Maxwell & Wilson, 2006, p. 225)___________ 
Early 
 Haemolytic reactions 
  Immediate 
  Delayed 
 Non-heamolytic febrile reactions 
 Allergic reactions to proteins, IgA 
 Transfusion-related acute lung injury 
 Reactions secondary to bacterial contamination 
 Circulatory overload 
 Air embolism 
 Thrombophlebitis 
 Hyperkalemia 
 Citrate toxicity 
 Hypothermia 
 Clotting abnormalities (after massive transfusion) 
Late 
 Tranmission of infection 
  Viral (hepatitis A, B, C, HIV, CMV) 
  Bacterial (Treponeum pallidum, Salmonella) 
  Parasites (malaria, toxoplasma) 
 Graft vs. host disease 
 Iron overload (after chronic transfusions) 
 Immune sensitization (Rhesus D antigen) 
______________________________________________________________________________ 
 
Currently, blood resuscitation of patients is guided by the clinical judgment of the 
anesthesia provider and standard coagulation tests such as activated partial thromboplastin time 
(aPTT), prothrombin time (PT), and international normalized ratio (INR) (Health Policy 
Advisory Committee on Technology, 2012, p. 9, Song, Jeong, Jun, Lee, & Hwang, 2014).  This 
type of management lags standardization in the amount, and type of blood products given to a 
patient, and lacks the ability to provide real-time care.  Standard coagulation tests take 
approximately 60-90 minutes to yield results and are unable to identify singular or multiple 
coagulation deficiencies, assess for rapid fibrinolysis, evaluate platelet dysfunction, or 
differentiate hemostatic response to tissue injury or surgery (Health Policy Advisory Committee 
on Technology, 2012, p. 9).   
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Increased transfusion by anesthesia providers during the intraoperative period is a 
concern in the overall quality of care of the perioperative patient.  Blood transfusions during liver 
transplant surgery have been associated with higher rates of infection, prolonged stay in intensive 
care units, immunologic effects on graft rejection, and increased patient mortality (Devi, 2009, 
Jabbour , et al., 2005; Hendriks, et al., 2001).  
Increased transfusion rates are also very costly to both the patient and hospital. Toner, et 
al., (2011), state after their cross-sectional randomized study (n=204), the cost for one unit of 
pack red blood cells was $210.74±37.9 US dollars and the average charge to the patient (n=167) 
was $346.63± 135 U.S. dollars (Toner et al., 2011, p. 36).  In this study there was statistical 
significance (p<0.0001) of acquisition of cost by different regions within the United States, as 
well as discounted rates to large teaching hospitals (Toner et al., 2011, p. 36). At The Ohio State 
University Wexner Medical Center (OSUWMC), the cost of one unit of pack red blood cells is 
$217.14, fresh frozen plasma is $39.87, a four pack of pooled platelets is $475.98, and a pack of 
cryoprecipitate is $335.33(OSU Wexner Medical Center Transfusion Services, 2014).  This cost 
is expected to increase due to the decline in blood donors.  The American Red Cross reports that 
due to the extensive screening process of donors for risk factors such as: travel, medication use, 
disease, and high-risk behaviors, it is estimated that only 38% of the United States population are 
eligible to donate blood, and  less than 10% of people eligible actually donate blood (American 
Red Cross, 2014).  Transfusion of blood products has also been linked to increased length of stay 
in intensive care units, increased overall hospital stay time, and increases in overall hospital 
costs. (Murphy, et al., 2007).  
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Purpose 
The purpose of this project is to examine the usage of Rotational Thrombolelastomety 
(RoTEM
®
) to guide blood resuscitation as a potential area to decrease patient exposure to blood 
products while decreasing overall hospital costs in the liver transplant program at the Ohio State 
University Wexner Medical Center.  
Significance to Nursing, Healthcare, and the DNP Essentials 
 Nursing, as well as many other healthcare specialties, are always looking for ways to 
improve patient outcomes.  The RoTEM
®
 produces quick, easily interpreted results that provide 
anesthesia providers with information on the patients underlying coagulation issues.  This 
information then allows providers to make better clinical judgments in order to provide 
individualized goal-directed blood resuscitation, giving the patient only the blood products that 
he/she requires.  This will help reduce the incidence of transfusion which can lead to 
complications and undesired patient outcomes.  
In today’s healthcare economy providers are forced to find new ways to decease overall 
costs while still providing high quality care.  The RoTEM
® 
allows for this high quality 
individualized care while also decreasing overall costs. 
The eight DNP essentials are: (1) understanding scientific underpinnings for practice, (2) 
being a leader in organizational and system improvements in order to advance thinking, (3) using 
clinical scholarship and analytical methods in evidenced based practice, (4) using information 
systems and technology for the improvement and transformation of care, (5) being a leader in 
healthcare advocacy and policy making, (6) being an integral part in interprofessional 
collaboration for improving patient and population health , (7) being an active participant in 
population health in order to improve overall nations’ health, and (8) to be a leader in advancing 
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the nursing profession (Zaccagnini & White, 2011).  The RoTEM
®
 allows for the use of new 
technology to transform care in order to advance thinking in the healthcare system. It also helps 
advance the nurse anesthesia profession by providing clinicians with more timely and specific 
data that assists in making faster and more informed decisions in the management of their 
patients care.   
PICO Question 
 In the perioperative patient [P], does the use of Rotational Thrombolelastomety (RoTEM) 
for guiding blood resuscitation [I] compared to the standard method [C], impact the overall 
amount of blood products given to the patient.[O]? 
Project Objectives 
 Illustrate that the use of Rotational Thrombolelastomety (RoTEM®) to guide 
blood resuscitation as a potential area to decrease patient exposure to blood 
products.  
 Examine the amount of blood products given to patients during the intraoperative 
period and 24hr post-op period in liver transplant patients  before and after 
implementation of the RoTEM
®
  




Running head: ROTEM to Guide Blood Resuscitation 10 
 
Chapter II: Review of the Literature 
The RoTEM
®
 is a device that evaluates a sample of whole blood and measures the 
viscoelastic properties during multiple aspects of blood coagulation (Health Policy Advisory 
Committee on Technology, 2012, p. 1). It provides information to the healthcare provider on the 
cause of the patient’s bleeding.  It determines the clotting time, the dynamics of the blood clot 
formation, clot stability and lysis, speed of initial fibrin formation, and the influence of clotting 
factors and anticoagulants; providing an individualized differential diagnosis of coagulopathies 
(Health Policy Advisory Committee on Technology, 2012, p. 2, Kozek-Langenecker, 2005).   
The RoTEM
®
 is a mobile unit that can be transported easily and can provide results in 10-20 
minutes and preliminary results can be visualized within two minutes of starting the test (Health 
Policy Advisory Committee on Technology, 2012, p. 3).  Analysis of blood samples can be re-
evaluated 10 minutes after the administration of more blood products or coagulation factors, 
allowing for individualized goal-directed therapy (Gorlinger, et al., 2007). Rugeri et al. (2007) 
found that the RoTEM
® 
parameters correlated with current standard coagulation parameters and 
platelet counts (Rugeri et al., 2007). This study also found that the RoTEM
®
 was able to detect 
changes of in vivo coagulation issues within 10 minutes of running a sample, further supporting 
its usefulness as a point of care system (Rugeri et al., 2007).  This device is simple to use and can 
quickly distinguish between surgical bleeding and bleeding caused by coagulopathies (Health 
Policy Advisory Committee on Technology, 2012, p. 9).  
When using the RoTEM
®
, five predefined tests, the INTEM (ellagic acid activated 
intrinsic pathway), EXTEM (tissue factor triggered extrinsic pathway), HEPTEM (ellagic acid 
activated intrinsic pathway plus heparinase), APTEM (tissue factor activation plus aprotinin), 
and FIBTEM (with platelet inhibitor (cytochalasin D) evaluating the contribution of fibrinogen 
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to clot formation) are used (Theusinger, et al., 2010, "ROTEM: The bleeding management 
System," 2013).
 
 These predefined tests differ from standard coagulation tests of fibrinogen, 
prothrombin time, and activated partial thromboplastin time because they are performed on 
whole blood rather than plasma, and it measures the process involving thrombin generation, clot 
formation, and lysis.  Standard tests only look at the processes leading up to the initial generation 
of thrombin (Theusinger et al., 2010). Within the predefined tests there are several parameters 
used to describe the dynamics of the blood clot (Health Policy Advisory Committee on 
Technology, 2012, Theusinger, et al., 2010, "ROTEM: The bleeding management System," 
2013).  Clotting time (CT) is from the start of the analysis until the start of the clot formation.  
Clot formation time (CFT), or the period that it takes until amplitude of 20mm (firmness) is 
reached (Theusinger et al., 2010).  The alpha angle is the angle between the center line and a 
tangent to the curve through the 2-mm amplitude point (Theusinger et al., 2010).  A10 and A20 
are the amplitudes 10 and 20 minutes after clotting time.
 
 MCF is the maximum amplitude of the 
curve or maximum clot firmness (Theusinger et al., 201).  ML represents the maximum 
fibrinolysis detected during the measurement and LI30 and LI60 represent lysis indexes 30 and 
60minutes after the clotting time (Theusinger, et al., 2010, "ROTEM: The bleeding management 
System," 2013).   
Figure 1: RoTEM reactive curve and coagulation parameters ("ROTEM: The bleeding 
management System," 2013) 
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In 2011, and again in 2013, the Cochrane Collaboration published a qualitative review on 
the use of Thrombelastography (TEG) or thromboelastometry (ROTEM
®
) to guide blood 
resuscitation in patients undergoing massive blood transfusion (Afshari, Wikkelso, Brok, Molier, 
& Westlerslv, 2011). In this review 2560 articles were examined pertaining to the use of the TEG 
and or RoTEM
®
 and 2537 were excluded due to their irrelevance, bias, duplication of other 
studies, and incompleteness of data (Afshari et al., 2011).  Twelve additional articles and two 
trials were further excluded due to no preliminary results, leaving a total of 9 studies to be 
evaluated (Afshari et al., 2011).  Data from the nine relevant studies were compiled and yielded 
an overall sample size of 776 patients (Afshari et al., 2011).   To combine the studies a Chi test 
with a P ≤ 0.1 was considered significant to provide an indication of heterogeneity between 
studies (Afshari et al., 2011, p. 12).  These studies showed that the use of the RoTEM
®
 decreased 
the amount of overall mortality (9/238 deaths in the TEG/RoTEM
®
 group, compared to 12/235 
in the control group), but this rate was unfortunately not statistically significant (Afshari et al., 
2011, p. 18).  The review found statistical significance though in a reduction of the overall 
amount of post-operative bleeding of patients in TEG/RoTEM
®
 group verse the control group, 
and a reduction in the total amount of blood products needed in patients receiving both Fresh 
Frozen Plasma (FFP) and platelets (Afshari et al., 2011, p. 18).  The overall conclusion of the 
review was that more controlled studies with minimal bias are required to further evaluate the 
benefits for the usage of the RoTEM
®
 (Afshari et al., 2011).  
The American Society of Anesthesiologists (2015) recently added the use of the 
RoTEM® to their practice guidelines for perioperative blood management after the organizations 
qualitative literature review (American Society of Anesthesiologists, 2015, p. 243).   The ASA 
suggest the use of point-of care testing such as the RoTEM®, to identify areas where 
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interventions can be employed (ASA, 2015).  In order to evaluate the literature the ASA placed 
the evidence into different levels of scientific evidence. To be considered category A evidence, 
their highest category, randomized control trials had comparative findings between clinical 
interventions for specified outcomes (ASA, 2015).  Statically significant (P<0.01) outcomes 
were designated as either beneficial(B) or harmful(H) to the patient; or statistically 
nonsignificant  evidence was designated as equivocal(E) (ASA, 2015,p.243). This category is 
then broken down into two levels that refer to the strength and quality of the literatures evidence 
(ASA, 2015).  Level 1 was literature that contained a sufficient number of randomized control 
trials to conduct meta-analysis, and a level 2 was literature that contained multiple randomized 
control trails but the number of randomized control trails was not sufficient to conduct a variable 
meta-analysis (ASA, 2015,p.243).  In these guidelines the ASA found category A2-E evidence 
that there are variable findings regarding blood and blood product usage with the usage of 
protocols and algorithms (ASA, 2015).  Category A2-B evidence was found in that there are 
reduced blood transfusions with TEG-guided protocols/ algorithms in cardiac surgery patients 
(ASA, 2015).  Lastly, category A1-B evidence was found in the reduction in allogenic blood 
product requirements with the usage of a RoTEM
®
 algorithm in burn patients (ASA, 2015).  
Gorlinger, et al. (2011), reported in a retrospective study of a university hospital (n= 
3,865), a 50% reduction in the incidence of massive transfusion (1.3% verse 2.5%, p= 0.006), as 
well as a decrease in the need for surgical re-exploration post-operatively (2.2% verse 4.2%, 
p=0.0007) after implementation of the RoTEM
®
 as a point-of-care system (Gorlinger, Dirkman, 
& Et al, 2011).  Anderson and colleagues (2006) further support these finding through their 
clinical audit of a cardiac intensive care unit, where they found significantly fewer amounts of 
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patients requiring blood products after the implementation of the RoTEM
®
 as a point-of-care 
system (Anderson, et al., 2006).    
Song and colleagues (2014) support the use of the RoTEM
®
 through their retrospective 
single institutional study of liver transplant patients (n=236), who typically have massive 
bleeding (Song et al., 2014).  This study showed (86% sensitivity and: 77% specificity) of 
current lab parameters correlating with the RoTEM
®
 parameters (Song et al., 2014).  It wasalso 
concluded that the RoTEM
®
 had more rapid results and was able to predict thrombocytopenia 
and hypofibrinogenaemia in this specific patient population (Song, et al., 2014).   
When looking at the financial aspects of RoTEM
®
, the costs to run the tests are 
comparable to the standard lab tests that are done currently.  Also due to the devices simplicity 
the RoTEM
®
 requires no advanced training or skill to perform (Health Policy Advisory 
Committee on Technology, 2012, p. 10).  See Table 2 for cost analysis. In addition to the cost of 
performing the test, the price for maintenance agreements for the RoTEM is $3,190.00 per year.  
Although, when factoring in this cost, keep in mind that many hospitals don’t account for the 
maintenance of their standard lab machines and storage when evaluating their budgets 
("ROTEM: The bleeding management System," 2013).  Many hospitals have found an overall 
cost savings when using the RoTEM.  Gorlierger and colleagues (2008) reported an overall cost 
savings of 35% (Gorlinger, et al., 2008), and Spalding and Harturmpf (2007), reported an overall 
cost savings of 44% after implementation of the use of the RoTEM.  Hass and colleagues (2014) 
also reported a 17.1% mean total cost per patient decrease after implantation of the RoTEM 
(Haas, Goobie, Spielmann, Weiss, & Schmugge, 2014). 
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Table  2: Cost Analysis of the RoTEM verse current standard tests (Health Policy Advisory 
Committee on Technology, 2012, p. 11) ** HEPTEM only needs to be run if the patient was 
anticoagulated with heparin.   
_____________________________________________________________________________________ 
Item  ROTEM delta    Standard Laboratory Tests 
Equipment $37,000    na 
 
Cost of tests* EXTEM – $13.40   aPTT – $10.69 
  INTEM - $13.40   PT – $10.69 
  FIBTEM - $16.77   Platelet count – $15.95 
  HEPTEM - $17.08   Fibrinogen - $44.58 
  APTEM - $19.45 
  *(costs inclusive of ROTEM pin, pipettes and reagents required) 
 
Total costs/ $80.10     $81.91 
Set of tests 
 
Maintenance ROTEM - $3190.00/year  na  
Agreements 
Legend: EXTEM= Tissue factor activation via extrinsic pathway; aPTT=activated partial thromboplastin 
time; INTEM= ellagic acid activated intrinsic pathway; PT=prothrombin time; FIBTEM= tissue factor 
activation plus platelet inhibition; HEPTEM= contact activation with heparinase; APTEM= EXTEM 
based assay in which fibrinolysis is inhibited by aprotinin in the reagent   
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Chapter III: Methods 
 
Project Design:  
 This quality process project used a retrospective de-identified case review of liver 
transplant surgical cases at the Ohio State University Wexner Medical Center’s (OSUWMC) 
Perioperative Unit from July 2012 to July 30, 2014.   
Sample:  
A convenience sample of human patients that underwent liver transplant surgery from 
July 2012 to July 30, 2014 at OSUWMC was examined.  This patient population was chosen 
because they typically yield massive blood losses and require large amounts of blood products 
during the perioperative period (Alkozai, Lisman, & Porte, 2009). Also this patient population 
has utilized the RoTEM
® 
for transfusion resuscitation during the intraoperative period within 
OSUWMC.  
Methods 
Approval from the OSUWMC Clinical Affairs and Patient Safety department was 
obtained and the project was designated a Quality Improvement project. Since the project was 
declared a quality improvement project, the IRB ruled the project IRB exempt.   
This quality process project used the liver transplant department’s quality database to 
examine blood product utilization.  The database was examined after all patient identifiers were 
removed.  Liver transplant cases from July 2012 to July 30, 2014 were included and placed into 
two categories; cases that utilized the RoTEM
®
 and cases that did not.    
In order to assess patient’s acuity level and degree of severity of liver disease between the two 
groups, each case was assessed for a model for end-stage liver disease (MELD) score. This score 
assesses the three parameters of serum bilirubin, INR, and serum creatinine, and has been 
adopted by the United Network of Organ Sharing in the United States as the gold standard in 
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order to prioritize patients for donor transplant (Kaufman & Roccaforte, 2001).  It has been 
reported in the literature that a MELD scores can be a predictor for three month non-operative 
mortality (Wiesner et al., 2003, p. 91).  See table 3. 
Table 3:  MELD Score Coorlation With Three Month Non-Operative Mortality 
   
  
 
After the MELD score was evaluated the type and number of blood products received 
during the intraoperative period was recorded.  These blood products included the number of 
pack red blood cells (pRBC), fresh frozen plasma (FFP), platelets (pLT), and cryoprecipitate 
(cryo).  The total number of pRBC given in the first 24hrs post-op was also evaluated. In 
addition to this, the total cost of blood products per case were calculated using the OSU Wexner 
Medical Center’s institutional costs per product.  
 It was anticipated that ROTEM use to guide blood product resuscitation therapy will 
show an overall decrease in the amount of blood products that a patient receives. This quality 
project will demonstrate to the organization a potential area for future research in overall cost 
reductions for the institution while increasing patient outcomes. 
All information was stored in a password protected electronic file with access by only 
those directly assisting in the project, and de-identified data files were maintained by the advisor 
according to IRB requirements in a locked cabinet in a locked office.    
Data Analysis 
 An Excel spreadsheet was created to store unidentified information.  This allowed for 
percentile comparison between the RoTEM and non-RoTEM groups.  The data was used to 
describe cost reduction and reduction of patient blood product exposure.  Intra-operative blood 
  MELD SCORE    
 <9       10-19 20-29 30-39 >40 
3 Month Non-Operative Mortality 1.9%           6% 19.6% 60.2% 79.3% 
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product reduction trends were calculated with an excel algorithm that looked at the total amount 
of individual blood products given during each of the 53 cases and compared these totals 
between the two groups.  To assess intra-operative cost reduction trends, the cost that The Ohio 
State University Wexner Medical Center (OSUWMC) pays for each  blood product was used.  
The cost of one unit of pack red blood cells (pRBC) is $217.14, fresh frozen plasma (FFP) is 
$39.87, a four pack of pooled platelets is $475.98, and a pack of cryoprecipitate (cryo) is 
$335.33(OSU Wexner Medical Center Transfusion Services, 2014).  The total number of 
products used for each patient for  each blood product (pRBC, FFP, platelets, and cryo) was 
multiplied by the product’s individual cost.  The total cost of all the  products given per each of 
the 53 cases was then computed. These totals where then averaged between the two groups and 
compared.  The 24hr post-surgery pRBC usage was calculated by evaluating the number of 
pRBCs each patient received in the 24hours post-surgery. The mean was calculated and then 
compared  between the two groups.  The 24hr pRBC cost was calculated by once again 
evaluating the number of pRBC given to each patient and multiplying it by the cost to the 
institution for one unit ($217.14).  The average cost was calculated for each group and then 
compared.  
 To evaluate the data for statistical significance a comparison T-test was performed.  In 
addition to this, a Mann Whitney U non parametric test was performed to compare the 
summation of ranks between the two groups.  Since readmission to the operating room for 
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Chapter IV: Findings 
Results 
Description of the Sample 
 During the time period from July 1, 2012 to July 30, 2014 at the OSUWMC a total of 53 
patients underwent liver transplant surgery.  Among these patients the RoTEM
®
 was used on 
twenty-five patients, twenty-eight patients were in the comparison group.  An average MELD 
score of 24.6 was found in both groups. 
Average Blood Product Usage 
 The non-RoTEM
®
 group had an average of 20 total units of intraoperative products that 
were given, while the RoTEM
®
 group had an average of 13 total units given during the 
intraoperative period; a 34.78% reduction in intraoperative product usage per case when utilizing 
the RoTEM
®
.  There was an average of 5 less units of FFP given per case in the RoTEM
®
 group; 
a 50.1% reduction.   Every category except cryoprecipitate had a reduction in the amount of 
products given in the RoTEM
®
 group. See Table 4.   
Table 4: Descriptive comparison for Intraoperative Product Usage:  
Average Hospital Costs for Intraoperative Product Administration  













 Used       
No 28 5.78 10.42 2.53 1.42 20.18 
Yes 25 3.96 5.20 2.10 1.88 13.16 
       
 Difference in 
Usage 
1.82 5.22 0.43 -0.46 7.02 
 Percentage 
Difference 
31.5% 50.1% 16.9% -32.4% 34.78% 
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 In the Non- RoTEM
®
 group the average hospital cost for intra-operative product usage 
was $3,358.09, while the average cost in the RoTEM
®
 group was $2,706.70.  This is a difference 
of $651.39 or 19.4% between the two groups. Table 5 describes the findings from this process.  
Table 5: Description of the Average Hospital Costs for Administered Intraoperative 
Product 





Average 24hr Post Surgery pRBC Usage and its Cost to the Hospital 
 In the Non- RoTEM
®
 group patients received an average of 3.07 units of pRBCs in the 
24hrs immediately following surgery, while the RoTEM
®
 group received an average of 1.56 
units of pRBCs.  Fourteen of the 25 patients in the RoTEM
®
 group required no pRBCs 24hrs 
post-op. 
 Using the OSUWMC’s institutional cost for one unit of pRBCs ($217.14), the average 
charge to the Medical Center for 24hr post-operative transfusion in the non- RoTEM
®
 group is 
$667.50 compared to the $338.74 charge in the RoTEM
®
 group.  This is a $328.77 or 49.25% 
difference in cost between the two groups. Table 6 describes these differences. 
Table 6: Average 24hr Post Surgery pRBC usage and Hospital Costs 
Readmission to the Operating Room for Bleeding 
RoTEM
®
 Used Cases Analyzed Average Hospital Cost 
No 28 $3,358.09 
Yes 25 $2,706.70 
   
 Difference in Cost $651.39 
 Percentage Difference 19.40% 
RoTEM
®
  Used Cases Analyzed Average 24hr post pRBCs 
Units 
Average 24hr Post pRBC Cost 
No 28 3.07 $667.50 
Yes 25 1.56 $338.74 
    
 Difference  1.51 $328.77 
 Percentage Difference   49.25% 
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The cases were then evaluated for post-operative bleeding that required surgical 
intervention.  In the non- RoTEM
®
 group six patients had to return to the OR, while only two 
had to return in the RoTEM
®
 group.  This is a 66.67% reduction in post-operative surgical 
intervention for bleeding. See Table 7.  




 After performing a comparison T-test, and a Mann-Whitney U test, none of the findings 
were statistically significant because of the low sample size and decreased power. This makes it 
impossible to either accept or reject the hypothesis.   
Financial Impact of the Device  
According to Tem Innovations GmbH, the inventors and distributers of the RoTEM
®
 
machine, the cost to purchase a device is $59,000, and typically has an estimated useful life of 5-
10 years (Tem Innovations GmbH , 2015).  After examining the liver transplant population in 
this project, the results indicate an average total cost savings of $990.13 per case.  This breaks 
down to an average of $651.39 savings per case in intra-operative blood products and an average 
of $338.74 savings in blood product usage 24-hours post-operatively.  Accordingly, this would 
require 60 cases to be performed to cover the original purchase price of the machine.  In the 
RoTEM
®
 Used Cases Analyzed Readmission to the OR for Bleeding 
No 28 6 
Yes 25 2 
   
 Difference  4 
 Percentage Difference 66.67% 
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tested population, if thirty cases are completed per year, the original purchase price of the 
machine would be covered within the first two years of operation, which provides an additional 









Although, none of the calculated values were statistically significant there are some 
promising trends that should be noted from this population and project.  First is the actual cost 
and efficiency of performing the actual point-of-care test with the RoTEM
®
.  It is $1.81-$18.89 
cheaper, depending if a HEPTEM needs to be performed, when using the RoTEM
®
 verses the 
standard method (Health Policy Advisory Committee on Technology, 2012, p. 11).  Also with 
the RoTEM
®
 an anesthesia provider can obtain lab results within 2-10 minutes, verses an hour 
with the standard technique (Song,et al., 2014). These quick results are extremely important in 
this population since their condition can change very rapidly making it almost impossible to have 
the same conditions an hour after sending labs.  Thus, the RoTEM
®
 allows a cheaper and quicker 
way to provide individualized care. 
 The results of this project are also consistent with previously discussed studies, showing a 
decrease in overall blood products given to patients both intra-operatively and post-operatively.  
Any decrease in blood product administration helps minimize patient’s risk of obtaining possible 
transfusion reactions and side effects.  Any reaction as a result of blood product administration 
can be extremely costly to the patient and the institution.  Adding yet another potential cost 
saving area for the hospital by using the RoTEM
®
.  
 In addition to the need of future projects examining a larger sample size within the tested 
population, studies utilizing the RoTEM
®
 in other patient populations that require larger amounts 
of blood transfusion such as cardiac and neurological patients should be examined.  If future 
quality projects on the RoTEM
®
 can prove the trend of decreased product usage in these areas, it 
could potentially lead to an even greater margin of savings to the hospital based on better 
Running head: ROTEM to Guide Blood Resuscitation 24 
 
utilization of the machine.  By using electronic health record systems, one machine can be 
utilized for multiple types of cases because results can be watched in real-time in the operating 
room with the machine in a different location.  As the usage of the machine is increased, the 
fixed cost associated with each case become smaller and smaller which, in turn, increases the 
profit margin of each case.  
Implications for Nursing Practice and the DNP Essentials  
 Doctor of Nursing Practice (DNP)- prepared nurses are in the unique position to be the 
leaders of using technology for the improvement and transformation of care.  This technology 
gives advanced practice nurses an easy and quick way to interpret what is going on with the 
patient intra-operatively in order to provide the most beneficial care.  The usage of this 
technology can also help decrease the amount of exposure to blood products that patients 
experience by giving them only the products required, thus helping to decrease complications 
associated with blood product administration.     
The DNP nurse is also in the unique position to be a leader in the development of new 
policies, procedures, and protocols.  They are the clinical experts and have the upper hand in 
knowing what is and isn’t practical when projects are done in the perioperative environment. 
This is an important skill that helps to avoid spending money and resources on projects that don’t 
have as much clinical impact.  The DNP is also able to interpret the research findings from more 
controlled settings and is able to interpret and incorporate the findings into practice, giving them 
the skills to be the leaders in program and protocol implementation.     
Limitations 
 A limitation of this project is the small sample size.  It is not possible to make 
generalizations about the presence or absence of statistical significance.  In order to address this 
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limitation, the data should be collected over a longer time frame in order to include a large 
sample size.  It is also possible that one should look at the volume (mL) of product given to the 
patient rather than whole units. 
 Being a retrospective project there are less controls that can be implemented, such as 
accounting for different anesthesia providers.   With the use of different providers there may be 
alack of consistency in management of blood transfusion based on the device results.  The 
RoTEM
®
 is only as good as the individual interpreting its results.  Providers need to be educated 
on results interpretation and develop a consistent protocol for treatment of different 
coagulopathies. A protocol will ensure that one individual isn’t giving a more costly product like 
cryoprecipitate for a particular coagulopathy while another is giving more fresh frozen plasma.   
Conclusions  
   Although  the findings were not statistically significant, there are some promising trends 
that should be noted from this project.  This project has shown a trend in the amount of blood 
product exposure patients experience with the utilization of the RoTEM
®
.  It also has highlighted 
an area of potential cost savings to the institution.  Future quality projects and research studies 
with a larger population size would be beneficial in order to better determine significance and 
generate generalizable information related to the impact of the RoTEM
®
 on blood product 
utilization.  
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